Anti-osteoporotic therapy in Denmark - Predictors and demographics of poor refill compliance and poor persistence

Osteoporosis International

Volumn 24, Issue 7, 2013, Pages 2079-2097

  Hansen, C ^a,b   Pedersen, B D ^a   Konradsen, H ^b   Abrahamsen, B ^b,c  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Osteoporosis; Persistence; Refill compliance; Register based; Risk groups; Socioeconomic

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; ANTILIPEMIC AGENT; ANTIPARKINSON AGENT; BISPHOSPHONIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBANDRONIC ACID; PREDNISOLONE; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLLAGEN DISEASE; COMORBIDITY; DEMENTIA; DEMOGRAPHY; DENMARK; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; INCOME; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETIREMENT; RISK ASSESSMENT; RISK FACTOR; SOCIOECONOMICS; SURVIVAL; TREATMENT DURATION; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COMORBIDITY; DENMARK; DIPHOSPHONATES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; POLYPHARMACY; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 84879236006     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2221-5     Document Type: Article

References (34)

1. Cadarette SM, Burden AM (2010) Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol 22(4):397-403. doi: 10.1097/BOR.0b013e32833ac7fe
2. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J et al (1999) Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10(4):259-264. doi: 10.1007/s001980050224
3. Sundhedsstyrelsen. Sund hele livet - de nationale mål og strategier for folkesundheden 2002-10. http://www.folkesundhed.dk/media/sundhelelivet.pdf. 2008
4. WHO. The World Health Report. http://www.who.int/whr/2008/en/index.html. 2008
5. Reginster JY, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2 Suppl 1):S4-S9. doi: 10.1016/j.bone.2005.11.024
6. Christensen PM, Brixen K, Gyrd-Hansen D, Kristiansen IS (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 96(5):387-396. doi: 10.1111/j.1742-7843.2005.pto-08.x
7. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20(10):1633-1650. doi: 10.1007/s00198-009-0920-3
8. Cooper C, Harvey NC (2012) Osteoporosis risk assessment. BMJ 344:e4191. doi: 10.1136/bmj.e4191
9. Landfeldt E, Strom O, Robbins S, Borgstrom F (2012) Adherence to treatment of primary osteoporosis and its association to fractures - the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433-443. doi: 10.1007/s00198-011-1549-6
10. Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20(2):299-307. doi: 10.1007/s00198-008- 0651-x
11. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81(8):1013-1022, AN 21973041
12. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21(11):1943-1951. doi: 10.1007/s00198-009-1134-4
13. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82(12):1493-1501, AN 27828553
14. Silverman S, Gold DT (2010) Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord 11(4):275-280. doi: 10.1007/s11154-010-9138-0
15. Lindberg MJ, Andersen SE, Christensen HR, Kampmann JP (2008) Compliance to drug prescriptions. Ugeskr Laeger 170(22):1912-1916
16. WHO. Adherence to long-term therapies evidence for action. http://www.who.int/chp/knowledge/publications/adherence-full-report.pdf. 2008.
17. Balkrishnan R (1998) Predictors of medication adherence in the elderly. Clin Ther 20(4):764-771. doi: 10.1016/S0149-2918(98)80139-2
18. Barat I, Andreasen F, Damsgaard EM (2001) Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol 51(6):615-622. doi: 10.1046/j.0306-5251.2001.01401.x
19. Ciechanowski PS, Katon WJ, Russo JE, Walker EA (2001) The patient-provider relationship: attachment theory and adherence to treatment in diabetes. Am J Psychiatry 158(1):29-35. doi: 10.1176/appi.ajp.158.1.29
20. DiMatteo MR (2004) Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 23(2):207-218, AN: 00003615-200403000-00014
21. Griffith S (1990) A review of the factors associated with patient compliance and the taking of prescribed medicines. Br J Gen Pract 40(332):114-116, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1371078/pdf/ brjgenprac00082-0026.pdf
22. Lassen LC (1989) Patient compliance in general practice. Scand J Prim Health Care 7(3):179-180, http://informahealthcare.com/doi/pdf/10.3109/ 02813438909087237
23. Block AE, Solomon DH, Cadarette SM, Mogun H, Choudhry NK (2008) Patient and physician predictors of post-fracture osteoporosis management. J Gen Intern Med 23(9):1447-1451. doi: 10.1007/s11606-008-0697-7
24. Cortet B, Benichou O (2006) Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis? Joint Bone Spine 73(5):e1-e7. doi: 10.1016/j.jbspin.2006.02.006
25. McLeod KM, Johnson CS (2011) A systematic review of osteoporosis health beliefs in adult men and women. J Osteoporos 2011:1-11. doi: 10.4061/2011/197454
26. Danmarks Statistik. Statistikbanken. http://www.statistikbanken.dk/ statbank5a/default.asp?w=1280 2008
27. Barker C (2009) The mean, median, and confidence intervals of Kaplan-Meier survival estimate - computations and applications. Am Stat 63(1):78-80. doi: 10.1198/tast.2009.0015
28. Nielsen DS, Langdahl BL, Sorensen OH, Sorensen HA, Brixen KT (2010) Persistence to medical treatment of osteoporosis in women at three different clinical settings - a historical cohort study. Scand J Publ Health 38(5):502-507. doi: 10.1177/1403494810371243
29. Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ (2012) Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf 21(3):297-304. doi: 10.1002/pds.2344
30. Wastesson JW, Ringback WG, Parker MG, Johnell K (2012) Educational level and use of osteoporosis drugs in elderly men and women: a Swedish nationwide register-based study. Osteoporos Int. doi: 10.1007/s00198-012-1945-6
31. Sale JE, Beaton DE, Sujic R, Bogoch ER (2010) 'If it was osteoporosis, I would have really hurt myself'. Ambiguity about osteoporosis and osteoporosis care despite a screening programme to educate fragility fracture patients. J Eval Clin Pract 16(3):590-596. doi: 10.1111/j.1365-2753.2009.01176.x
32. Meadows ES, Mitchell BD, Bolge SC, Johnston JA, Col NF (2012) Factors associated with treatment of women with osteoporosis or osteopenia from a national survey. BMC Womens Health 12:1. doi: 10.1186/1472-6874-12-1
33. Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55(5):729-735. doi: 10.1002/art.22229
34. Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP (2005) Interventions to enhance medication adherence. Cochrane Database Syst Rev (4):CD000011. DOI: 10.1002/14651858.CD000011.pub3